NCT06226064View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

October 11, 2023

Primary Completion Date

July 26, 2024

Study Completion Date

July 26, 2024

Conditions
Dementia, Frontotemporal
Interventions
DRUG

VES001

VES001 is an oral, blood brain barrier penetrating ligand of sortilin.

DRUG

Placebo

A matching dosage form, indistinguishable from the active treatment will be used as the placebo treatment.

Trial Locations (1)

2333

Center for Human Drug Research, Leiden

All Listed Sponsors
lead

Vesper Biotechnologies ApS

INDUSTRY

NCT06226064 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants | Biotech Hunter | Biotech Hunter